NHS

News

NICE clears NHS use of Roche's Tecentriq in bladder cancer

NICE has recommended routine NHS access to Roche's cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (C

R&D

Early detection of cancers will require blood sweat and tear...

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

Patients

Taking stock of NHS medicines optimisation

Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at loc

News

NHS England starts largest ever trial of Galleri cancer bloo...

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects.<

News

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

Amgen's first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness is appraised

NICE clears NHS use of Roche's Tecentriq in bladder cancer

Early detection of cancers will require blood sweat and tear...

Keytruda backed by NICE for late-stage oesophageal cancer

Taking stock of NHS medicines optimisation

NHS England starts largest ever trial of Galleri cancer bloo...

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

NHS

Editor's Picks